134 related articles for article (PubMed ID: 22223618)
1. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial.
Bould H; Wiles N; Potokar J; Cowen P; Nutt DJ; Peters TJ; Lewis G
J Psychopharmacol; 2012 May; 26(5):663-9. PubMed ID: 22223618
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism of the 5-HT transporter and response to antidepressants: randomised controlled trial.
Lewis G; Mulligan J; Wiles N; Cowen P; Craddock N; Ikeda M; Grozeva D; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Peters TJ
Br J Psychiatry; 2011 Jun; 198(6):464-71. PubMed ID: 21263010
[TBL] [Abstract][Full Text] [Related]
3. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.
Rampello L; Chiechio S; Nicoletti G; Alvano A; Vecchio I; Raffaele R; Malaguarnera M
Psychopharmacology (Berl); 2004 Apr; 173(1-2):73-8. PubMed ID: 14685645
[TBL] [Abstract][Full Text] [Related]
4. Severity of depression and response to antidepressants: GENPOD randomised controlled trial.
Wiles NJ; Mulligan J; Peters TJ; Cowen PJ; Mason V; Nutt D; Sharp D; Tallon D; Thomas L; O'Donovan MC; Lewis G
Br J Psychiatry; 2012 Feb; 200(2):130-6. PubMed ID: 22194183
[TBL] [Abstract][Full Text] [Related]
5. Citalopram versus other anti-depressive agents for depression.
Cipriani A; Purgato M; Furukawa TA; Trespidi C; Imperadore G; Signoretti A; Churchill R; Watanabe N; Barbui C
Cochrane Database Syst Rev; 2012 Jul; 7(7):CD006534. PubMed ID: 22786497
[TBL] [Abstract][Full Text] [Related]
6. Randomized double-blind comparison of serotonergic (Citalopram) versus noradrenergic (Reboxetine) reuptake inhibitors in outpatients with somatoform, DSM-IV-TR pain disorder.
Aragona M; Bancheri L; Perinelli D; Tarsitani L; Pizzimenti A; Conte A; Inghilleri M
Eur J Pain; 2005 Feb; 9(1):33-8. PubMed ID: 15629872
[TBL] [Abstract][Full Text] [Related]
7. Are multiple physical symptoms a poor prognostic factor or just a marker of depression severity? Secondary analysis of the GenPod trial.
Green A; Crawford A; Button KS; Wiles N; Peters TJ; Nutt D; Lewis G
J Affect Disord; 2014 Jul; 163():40-6. PubMed ID: 24836086
[TBL] [Abstract][Full Text] [Related]
8. Differential prediction of first clinical response to serotonergic and noradrenergic antidepressants using the loudness dependence of auditory evoked potentials in patients with major depressive disorder.
Juckel G; Pogarell O; Augustin H; Mulert C; Müller-Siecheneder F; Frodl T; Mavrogiorgou P; Hegerl U
J Clin Psychiatry; 2007 Aug; 68(8):1206-12. PubMed ID: 17854244
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in depressive symptoms and tolerability after treatment with selective serotonin reuptake inhibitor antidepressants: Secondary analyses of the GENPOD trial.
Gougoulaki M; Lewis G; Nutt DJ; Peters TJ; Wiles NJ; Lewis G
J Psychopharmacol; 2021 Aug; 35(8):919-927. PubMed ID: 33637001
[TBL] [Abstract][Full Text] [Related]
10. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study.
Seedat S; van Rheede van Oudtshoorn E; Muller JE; Mohr N; Stein DJ
Int Clin Psychopharmacol; 2003 Sep; 18(5):279-84. PubMed ID: 12920388
[TBL] [Abstract][Full Text] [Related]
11. Adverse effects from antidepressant treatment: randomised controlled trial of 601 depressed individuals.
Crawford AA; Lewis S; Nutt D; Peters TJ; Cowen P; O'Donovan MC; Wiles N; Lewis G
Psychopharmacology (Berl); 2014 Aug; 231(15):2921-31. PubMed ID: 24525810
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis.
Pjrek E; Konstantinidis A; Assem-Hilger E; Praschak-Rieder N; Willeit M; Kasper S; Winkler D
J Psychiatr Res; 2009 May; 43(8):792-7. PubMed ID: 19230909
[TBL] [Abstract][Full Text] [Related]
13. Basal prolactin values correlate with response to reboxetine treatment in major depression, but not with response to citalopram.
Moeller O; Hetzel G; Michael N; Rothermundt M; Arolt V; Erfurth A
Neuropsychobiology; 2005; 51(2):67-71. PubMed ID: 15741746
[TBL] [Abstract][Full Text] [Related]
14. Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
Berlanga C; Flores-Ramos M
J Affect Disord; 2006 Oct; 95(1-3):119-23. PubMed ID: 16782204
[TBL] [Abstract][Full Text] [Related]
15. The effect of serotonergic and noradrenergic antidepressants on face emotion processing in depressed patients.
Tranter R; Bell D; Gutting P; Harmer C; Healy D; Anderson IM
J Affect Disord; 2009 Nov; 118(1-3):87-93. PubMed ID: 19250683
[TBL] [Abstract][Full Text] [Related]
16. Diminished neural processing of aversive and rewarding stimuli during selective serotonin reuptake inhibitor treatment.
McCabe C; Mishor Z; Cowen PJ; Harmer CJ
Biol Psychiatry; 2010 Mar; 67(5):439-45. PubMed ID: 20034615
[TBL] [Abstract][Full Text] [Related]
17. Reboxetine plus citalopram for refractory depression not responding to venlafaxine: possible mechanisms.
Dursun SM; Devarajan S
Psychopharmacology (Berl); 2001 Feb; 153(4):497-8. PubMed ID: 11243498
[No Abstract] [Full Text] [Related]
18. Is there a role for a pure noradrenergic drug in the treatment of depression?
Montgomery SA
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S3-9; discussion S71-3. PubMed ID: 9169305
[TBL] [Abstract][Full Text] [Related]
19. Noradrenaline in basic models of depression.
Leonard BE
Eur Neuropsychopharmacol; 1997 Apr; 7 Suppl 1():S11-6; discussion S71-3. PubMed ID: 9169306
[TBL] [Abstract][Full Text] [Related]
20. Effect of reboxetine on major depressive disorder in breast cancer patients: an open-label study.
Grassi L; Biancosino B; Marmai L; Righi R
J Clin Psychiatry; 2004 Apr; 65(4):515-20. PubMed ID: 15119914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
